News

 

 

ASX BIOTECH STOCKS SURGE 54% IN 2013

7 January 2014: Analysis from leading healthcare fund manager BioScience Managers has highlighted the outstanding year for biotech stocks on the ASX in 2013 with an average gain of 53.6%* across...

Read more about ASX BIOTECH STOCKS SURGE 54% IN 2013

AmpliPhi Biosciences Announces $18 Million Private Placement

AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into a definitive stock purchase agreement to raise approximately $18 million in a private placement financing. 

Read more about AmpliPhi Biosciences Announces $18 Million Private Placement

Alchemia expands executive leadership team, appointing Thomas Liquard as Chief Operating Officer

ASX announcement here.

Read more about Alchemia expands executive leadership team, appointing Thomas Liquard as Chief Operating Officer

Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere

Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the “Company”) today announced that it has commenced dosing patients in the Northern Hemisphere portion of its ongoing Phase 2, randomized, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate (LANI). 

Read more about Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere

Avita Medical Update to Shareholders

ASX announcement link here.

Read more about Avita Medical Update to Shareholders

Scottish Medicines Consortium Accepts Bronchitol For Use In Cystic Fibrosis Patients

Pharmaceutical company Pharmaxis (ASX:PXS) today announced that the Scottish Medicines Consortium (SMC) has accepted Bronchitol® (mannitol dry powder for inhalation) for use by the National Health Service in Scotland.  Bronchitol is licensed for the treatment of adult cystic fibrosis (CF) patients aged 18 years and above as an add-on therapy to best standard of care.

Read more about Scottish Medicines Consortium Accepts Bronchitol For Use In Cystic Fibrosis Patients

Biota Initiates Additional Clinical Trials of Laninamivir Octanoate

Biota Pharmaceuticals Inc. (“Biota”) (Nasdaq:BOTA) announced today that it has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate (“LANI”), its long-acting neuraminidase inhibitor being developed for the treatment of influenza.

Read more about Biota Initiates Additional Clinical Trials of Laninamivir Octanoate

Bioxyne Ltd – Sale of HI-164OV Hunter Immunology Pty Ltd

Please find the ASX announcement here.

Read more about Bioxyne Ltd – Sale of HI-164OV Hunter Immunology Pty Ltd

Bioxyne Ltd CEO Steps Down

Bioxyne Limited (ASX code: BXN or the Company) advises that subsequent to the execution of a non-binding Heads of Agreement (HOA) to sell its HI-164 oral Vaccine project together with all of its Intellectual properties (IP) to Mariposa Health Limited (MHL), Dr. Phillip Comans has stepped down as Chief executive Officer of the Company. 

Read more about Bioxyne Ltd CEO Steps Down

Pharmaxis – AGM presentation and results

Chairman’s Address to 2013 Annual General Meeting here.

Read more about Pharmaxis – AGM presentation and results

1 ... 19 20 21 22 23 24